Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Bio Nebraska member, Pfizer, and BioNTech announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program. Read more